e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Y. S. Shim, H. J. Kim, S. M. Lee, J. J. Yim, C. G. Yoo, Y. W. Kim, S. K. Han (Seoul, Republic Of Korea)
Source:
Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Session:
Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Session type:
Oral Presentation
Number:
1325
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. S. Shim, H. J. Kim, S. M. Lee, J. J. Yim, C. G. Yoo, Y. W. Kim, S. K. Han (Seoul, Republic Of Korea). Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB. Eur Respir J 2007; 30: Suppl. 51, 1325
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Related content which might interest you:
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Source: Eur Respir J 2009; 33: 1085-1094
Year: 2009
Strategies against multidrug-resistant tuberculosis
Source: Eur Respir J 2002; 20: 66S-77S
Year: 2002
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005
The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007
Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre
Source: Eur Respir J 2003; 22: Suppl. 45, 524s
Year: 2003
MDR-TB and XDR-TB: drug resistance and treatment outcomes
Source: Eur Respir J 2009; 34: 778
Year: 2009
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
Source: Eur Respir J 2009; 33: 581-585
Year: 2009
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis
Source: Eur Respir J 2012; 39: 626-634
Year: 2012
Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Treatment results and follow up of patients with chronic multidrug resistant tuberculosis
Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Year: 2005
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country.
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019
Year: 2020
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 41: 1393-1400
Year: 2013
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis
Source: Eur Respir J 2010; 36: 870-877
Year: 2010
Multi-drug resistant tuberculosis (MDR-TB) in Ramnicul Valcear, Romania; drug treatment, resistance testing and adverse drug reactions
Source: Eur Respir J 2006; 28: Suppl. 50, 378s
Year: 2006
The prevalence of drug resistance tuberculosis in previously treated patients
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept